Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort-Reference-Cited by-同舟云学术

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort

Published:2024-08-21 Issue: Volume: Page:
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Tachibana Yusuke,Morimoto Kenji,Yamada Tadaaki,Kawachi Hayato,Tamiya Motohiro,Negi Yoshiki,Goto Yasuhiro,Nakao Akira,Shiotsu Shinsuke,Tanimura Keiko,Takeda Takayuki,Okada Asuka,Harada Taishi,Date Koji,Chihara Yusuke,Hasegawa Isao,Tamiya Nobuyo,Katayama Yuki,Nishioka Naoya,Iwasaku Masahiro,Tokuda Shinsaku,Kijima Takashi,Takayama Koichi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10637-024-01467-7.pdf

Reference29 articles.

1. Kawachi H, Fujimoto D, Morimoto T et al (2019) Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. Invest New Drugs 37:1257–1265. https://doi.org/10.1007/s10637-019-00770-y

2. Ishida M, Morimoto K, Yamada T et al (2023) Early tumor shrinkage as a predictor of favorable treatment outcomes in patients with extensive-stage SCLC who received programmed cell death-ligand 1 inhibitor plus platinum-etoposide chemotherapy: a prospective observational study. JTO Clin Res Rep 4:100493. https://doi.org/10.1016/j.jtocrr.2023.100493

3. McCoach CE, Blumenthal GM, Zhang L et al (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707–2714. https://doi.org/10.1093/annonc/mdx414

4. Jo H, Yoshida T, Yagishita S et al (2023) Clinical characteristics and pharmacokinetics change of long-term responders to antiprogrammed cell death Protein 1 inhibitor among patients with advanced NSCLC. JTO Clin Res Rep 4:100474. https://doi.org/10.1016/j.jtocrr.2023.100474

5. Xie X, Li X, Yao W (2021) A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Transl Cancer Res 10:1119–1130. https://doi.org/10.21037/tcr-20-2547